『CRISPR Turns Down the Bradykinin Dial』のカバーアート

CRISPR Turns Down the Bradykinin Dial

CRISPR Turns Down the Bradykinin Dial

無料で聴く

ポッドキャストの詳細を見る

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
On September 8, 2026, the FDA accepted Intellia’s biologics application for lonvo-z, a one-time in vivo CRISPR therapy for hereditary angioedema, and gave it Priority Review. That matters because a single gene edit in the liver could replace lifelong attack-prevention drugs for a rare swelling disease driven by excess bradykinin. The core MCAT hook is how loss-of-function CRISPR editing of *KLKB1* lowers plasma kallikrein and slows a proteolytic cascade that opens vessels and floods tissue. The lesson and three practice questions reinforce CRISPR mechanics, enzyme cascades, capillary permeability, autosomal-dominant genetics, and how to read a randomized Phase 3 trial.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません